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INTRODUCTION
In the face of the increasing worldwide problem of antimi-
crobial resistance, many classes of antimicrobial agents have
become less useful for therapy (1). Fluoroquinolones continued
to be used for the treatment of various infections, because they
are active against both Gram-positive, and Gram-negative
bacteria (2-4). However, resistance to the second-generation
fluoroquinolones has increased against many bacterial species.
Gemifloxacin is a new fluoroquinolones under development
with enhanced affinity for topoisomerase IV, and DNA gyrase,
and has the lowest minimum inhibitory concentrations (MICs)
against clinical isolates of Streptococcus pneumoniae (5-7). In
Korea, resistant bacteria are relatively more prevalent than
in other industrialized countries, and are a serious problem
currently (8). In this study, we tested the in vitro activity of
gemifloxacin, and comparative agents against recent Korean
bacterial isolates.
MATERIALS AND METHODS
A total of 1,689 clinical bacterial isolates were collected
from four Korean university hospitals during 1999-2000.
Neisseria gonorrhoeae isolates were obtained, mostly from female
patients. Identifications of species were performed by conven-
tional methods or through the usage of commercial kits. Iso-
lates were stored in skim milk at -70℃ until required.
Antimicrobial susceptibility was determined, using the
National Committee for Clinical Laboratory Standards
(NCCLS) agar dilution method (9) with Mueller-Hinton
agar (BBL, Cockeysville, MD, U.S.A.), except for strepto-
cocci, N. gonorrhoeae, and Haemophilus influenzae, for which
5% lysed sheep blood-supplemented Mueller-Hinton agar,
IsoVitaleX (BBL)-supplemented GC agar, and Haemophilus
Test Medium, respectively, were used. 
The antimicrobial agents used were: gemifloxacin (LGCI,
Seoul, Korea), gatifloxacin (Bristol-Myers Squibb, Princeton,
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In vitro Activity of Gemifloxacin Against Recent Clinical Isolates of
Bacteria in Korea
Gemifloxacin is an enhanced-affinity fluoroquinolone with broad-spectrum antibac-
terial activity. In Korea, resistant bacteria are relatively more prevalent than in other
industrialized countries. In this study, we studied the in vitro activities of gemifloxacin,
gatifloxacin, moxifloxacin, levofloxacin, ciprofloxacin, and other commonly used
antimicrobial agents against 1,689 bacterial strains isolated at four Korean university
hospitals during 1999-2000. Minimum inhibitory concentrations (MICs) were deter-
mined using the agar dilution method of National Committee for Clinical Laboratory
Standards. Gemifloxacin had the lowest MICs for the respiratory pathogens: 90% of
Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae were
inhibited by 0.06, 0.03, and 0.03 mg/L, respectively. Gemifloxacin was more active
than the other fluoroquinolones against methicillin-susceptible Staphylococcus aureus,
coagulase-negative staphylococci, streptococci, and Enterococcus faecalis. The
MIC90s of gemifloxacin for Klebsiella oxytoca, Proteus vulgaris, and non-typhoidal
Salmonella spp. were 0.25, 1.0, and 0.12 mg/L, respectively, while those for other
Gram-negative bacilli were 4-64 mg/L. In conclusion, gemifloxacin was the most
active among the comparative agents against Gram-positive species, including
respiratory pathogens isolated in Korea.
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NJ, U.S.A.), ciprofloxacin, and moxifloxacin (Bayer, Wupper-
tal, Germany), levofloxacin (Daiichi Pharmaceutical, Tokyo,
Japan), amoxicillin-clavulanic acid, and ceftazidime (Glaxo-
SmithKline, Harlow, U.K.), ceftriaxone (Roche, Basel,
Switzerland), imipenem (MSD, Elkton, VA, U.S.A.), specti-
nomycin (Upjohn, Bridgewater, NJ, U.S.A.), and penicillin G,
ampicillin, oxacillin, cefuroxime, erythromycin, gentamicin,
tetracycline, and vancomycin (Sigma, St. Louis, MO, U.S.A.).
The ratio of amoxicillin to clavulanic acid was 2:1. As the
breakpoints of ciprofloxacin for S. pneumoniae is not defined
by the NCCLS, the criteria used by Doern et al. (10) were
applied, i.e., an MIC ≥4 mg/L as resistant, and ≤1 mg/L as
susceptible. Quality controls were performed using Staphylococ-
cus aureus ATCC 29213, Enterococcus faecalis 29212, S. pneumo-
niae ATCC 49619, Escherichia coli ATCC 25922, Pseudomonas
aeruginosa ATCC 27853, N. gonorrhoeae ATCC 49226, H.
influenzae ATCC 49247 or H. influenzae ATCC 49766, depend-
ing on test organisms. 
RESULTS AND DISCUSSION 
The activities of gemifloxacin, and the other antimicrobial
agents against common respiratory pathogens are shown in
Table 1. All isolates of S. pneumoniae, except one, were inhibited
by ≤0.25 mg/L of gemifloxacin. One S. pneumoniae isolate
with a gemifloxacin MIC of 2 mg/L was inhibited by 32 mg/L
of levofloxacin, 64 mg/L of ciprofloxacin, 8 mg/L of moxi-
Streptococcus pneumoniae, all (103)
Gemifloxacin 0.015-2 0.03 0.06
Moxifloxacin 0.12-8 0.25 0.25
Gatifloxacin 0.03-8 0.5 0.5
Levofloxacin 0.5-32 1 2
Ciprofloxacin 0.5-64 2 4
Penicillin ≤0.008-8 2 4
Ceftriaxone 0.015-4 1 2
Erythromycin 0.03->128 128 >128









S. pneumoniae, Penicillin intermediate (16)
Gemifloxacin 0.015-0.12 0.03 0.06
Moxifloxacin 0.12-0.25 0.25 0.25
Gatifloxacin 0.06-0.5 0.25 0.5
Levofloxacin 1-2 1 2
Ciprofloxacin 0.5-4 1 4
Penicillin 0.12-1 0.5 1
Ceftriaxone 0.015-4 0.25 1
Erythromycin 0.03->128 64 >128
S. pneumoniae, Penicillin resistant (78)
Gemifloxacin 0.015-2 0.03 0.06
Moxifloxacin 0.12-8 0.25 0.25
Gatifloxacin 0.03-8 0.5 0.5
Levofloxacin 0.5-32 1 2
Ciprofloxacin 1-64 2 4
Penicillin 2-8 4 4
Ceftriaxone 0.12-4 1 2
Erythromycin 0.03->128 128 >128
Haemophilus influenzae, all (73)
Gemifloxacin ≤0.008-0.12 ≤0.008 0.03




Moxifloxacin ≤0.008-1 0.015 0.06
Gatifloxacin ≤0.008-0.5 0.015 0.03
Levofloxacin ≤0.008-0.25 0.015 0.06
Ciprofloxacin ≤0.008-0.25 0.015 0.03
Ampicillin 0.06->128 16 128
Cefuroxime ≤0.03-16 1 4
Ceftriaxone ≤0.008-32 ≤0.008 0.06
Amoxicillin-clavulanic acid ≤0.008-16 1 8
H. influenzae, -lactamase positive (48)
Gemifloxacin ≤0.008-0.12 ≤0.008 0.03
Moxifloxacin ≤0.008-1 0.03 0.06
Gatifloxacin ≤0.008-0.25 0.015 0.03
Levofloxacin ≤0.008-0.25 0.015 0.12
Ciprofloxacin ≤0.008-0.12 0.015 0.03
Ampicillin 4->128 32 128
Cefuroxime ≤0.03-16 1 4
Ceftriaxone ≤0.008-32 ≤0.008 0.06
Amoxicillin-clavulanic acid ≤0.008-16 2 8
H. influenzae, -lactamase negative (25)
Gemifloxacin ≤0.008-0.03 ≤0.008 0.03
Moxifloxacin ≤0.008-0.06 0.015 0.06
Gatifloxacin ≤0.008-0.5 0.015 0.03
Levofloxacin ≤0.008-0.12 0.015 0.06
Ciprofloxacin ≤0.008-0.25 0.015 0.03
Ampicillin 0.06-2 0.5 2
Cefuroxime 0.015-4 0.5 2
Ceftriaxone ≤0.008-1 0.015 0.06
Amoxicillin-clavulanic acid 0.015-16 1 4
Moraxella catarrhalis (60)
Gemifloxacin ≤0.008-0.03 0.015 0.03
Moxifloxacin ≤0.008-0.12 0.03 0.06
Gatifloxacin 0.03-0.25 0.03 0.06
Levofloxacin 0.03-0.5 0.06 0.06
Ciprofloxacin ≤0.008-1 0.03 0.06
Penicillin 0.5-32 16 32
Erythromycin 0.12-1 0.25 0.5
Tetracycline 0.25-1 0.5 1




Table 1. In vitro activity of gemifloxacin, and other antimicrobial agents against recent clinical isolates of Streptococcus pneumo-
niae, Haemophilus influenzae, and Moraxella catarrhalis
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floxacin, and 8 mg/L of gatifloxacin. Gemifloxacin (MIC90
0.06 mg/L) was 4 to 64-fold more potent than the other
quinolones (MIC90 0.25-4 mg/L), and ≥32-fold more potent
than the non-quinolone comparators (MIC90 2->128 mg/L) for
S. pneumoniae. The percentage of strains with a ciprofloxacin
MICs of ≥4 mg/L was 14%, and those with a levofloxacin
MICs of ≥8 mg/L was 1.5%. These results indicate that the
resistance rates were higher than in the United States (11), and
in Japan (12).  
Ninety-one percent of S. pneumoniae (94/103) were penicillin
non-susceptible, but 90% of the isolates were inhibited by
≤0.06 mg/L of gemifloxacin. These results were similar to
those from other reports (6, 7), although two studies from
North America showed a statistically significant association
between resistance to penicillin, and fluoroquinolone (13, 14).
In this study, the rates of -lactamase-producing H. influen-
zae, and Moraxella catarrhalis were found to be higher than
those reported in other countries, 66%, and 95%, respectively
Methicillin-susceptible Staphylococcus aureus (86)
Gemifloxacin 0.015-0.5 0.06 0.12
Moxifloxacin 0.03-32 0.12 0.25
Gatifloxacin 0.03-4 0.12 0.25
Levofloxacin 0.015-4 0.25 0.5
Ciprofloxacin 1-32 0.5 1
Oxacillin ≤0.12-2 0.5 1
Erythromycin ≤0.12->128 0.5 >128
Gentamicin ≤0.12->128 1 64
Vancomycin ≤0.12-2 1 1
Methicillin-resistant S. aureus (88)
Gemifloxacin 0.03->128 4 >128
Moxifloxacin 0.015->128 16 128
Gatifloxacin 0.06->128 8 >128
Levofloxacin 0.25->128 32 >128
Ciprofloxacin 0.25->128 64 >128
Oxacillin 4->128 >128 >128
Erythromycin 0.25->128 >128 >128
Gentamicin 0.5->128 128 >128
Vancomycin 0.5-2 1 2
Methicillin-susceptible coagulase-negative
staphylococci (60)
Gemifloxacin ≤0.008-1 0.03 0.12
Moxifloxacin 0.015-4 0.12 0.25
Gatifloxacin 0.015-4 0.12 0.25
Levofloxacin 0.03-8 0.25 0.25
Ciprofloxacin 0.015-8 0.25 0.5
Oxacillin ≤0.12-0.25 0.25 0.25
Erythromycin ≤0.12->128 0.25 >128
Gentamicin ≤0.12-128 0.5 16
Vancomycin ≤0.12-2 1 2
Methicillin-resistant coagulase-negative 
staphylococci (63)
Gemifloxacin ≤0.008-8 0.12 1
Moxifloxacin 0.015-8 0.25 4
Gatifloxacin 0.03-8 0.25 4
Levofloxacin 0.12-32 0.25 8
Ciprofloxacin 0.015->128 0.25 128
Oxacillin 0.5->128 4 128
Erythromycin ≤0.12->128 64 >128
Gentamicin 0.25->128 64 128
Vancomycin ≤0.12-2 1 2
Enterococcus faecalis (78)
Gemifloxacin ≤0.008-8 0.25 8
Moxifloxacin 0.06-32 0.5 16




Gatifloxacin 0.12-32 0.5 16
Levofloxacin 0.5-64 1 64
Ciprofloxacin 0.25-64 1 32
Ampicillin 0.25-8 1 4
Erythromycin 0.25->128 >128 >128
Tetracycline 0.5-128 64 128
Vancomycin 0.5-4 2 4
Enterococcus faecium (82)
Gemifloxacin 0.015-128 16 64
Moxifloxacin 0.03-64 16 32
Gatifloxacin 0.015-128 16 32
Levofloxacin 0.015->128 32 64
Ciprofloxacin ≤0.008->128 32 >128
Ampicillin 0.5->128 >128 >128
Erythromycin ≤0.12->128 >128 >128
Tetracycline 0.25->128 0.5 64
Vancomycin 0.25->128 1 >128
S. pyogenes (41)
Gemifloxacin 0.015-0.25 0.06 0.25
Moxifloxacin 0.015-0.5 0.25 0.5
Gatifloxacin 0.03-0.5 0.12 0.5
Levofloxacin 0.015-2 0.5 1
Ciprofloxacin 0.06-2 0.5 1
Penicillin ≤0.008-0.5 0.015 0.06
Ceftriaxone ≤0.008-0.06 0.015 0.03
Erythromycin 0.015->128 0.06 4
S. agalactiae (30)
Gemifloxacin 0.015-0.25 0.06 0.25
Moxifloxacin ≤0.008-0.25 0.25 0.25
Gatifloxacin 0.12-0.5 0.25 0.25
Levofloxacin 0.25-2 0.5 1
Ciprofloxacin 0.5-4 2 1
Penicillin ≤0.008-1 0.06 0.25
Ceftriaxone 0.015-0.5 0.06 0.12
Erythromycin 0.06->128 0.25 >128
Viridans streptococci (28)
Gemifloxacin ≤0.008-2 0.06 0.25
Moxifloxacin ≤0.008-8 0.25 0.5
Gatifloxacin ≤0.008-4 0.25 1
Levofloxacin ≤0.008-32 1 2
Ciprofloxacin ≤0.008-64 1 4
Penicillin ≤0.008-32 0.25 4
Ceftriaxone ≤0.008-32 0.12 2
Erythromycin ≤0.008->128 0.06 >128




Table 2. In vitro activity of gemifloxacin, and other antimicrobial agents against other Gram-positive aerobes
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Escherichia coli (81)
Gemifloxacin ≤0.008->128 0.12 64
Moxifloxacin ≤0.008-128 0.25 64
Gatifloxacin ≤0.008-64 0.06 8
Levofloxacin ≤0.008-128 0.25 16
Ciprofloxacin ≤0.008->128 0.12 >128
Ampicillin 2->128 >128 >128
Cefuroxime 1->128 4 32
Ceftriaxone ≤0.008->128 0.06 16
Imipenem 0.03-1 0.25 0.25
Amoxicillin-clavulanic acid 2->128 32 64
Gentamicin 0.25->128 1 >128
Klebsiella pneumoniae (81)
Gemifloxacin 0.03->128 0.06 4
Moxifloxacin 0.06->128 0.25 4
Gatifloxacin 0.015->128 0.06 2
Levofloxacin 0.03->128 0.06 4
Ciprofloxacin ≤0.008->128 0.03 2
Ampicillin 4->128 >128 >128
Cefuroxime 0.5->128 4 >128
Ceftriaxone 0.015->128 0.06 128
Imipenem 0.03-4 0.25 4
Amoxicillin-clavulanic acid 0.5->128 8 64
Gentamicin 0.25->128 0.5 >128
Klebsiella oxytoca (55)
Gemifloxacin ≤0.008-8 0.06 0.25
Moxifloxacin 0.03-8 0.12 1
Gatifloxacin 0.015-2 0.06 0.12
Levofloxacin 0.03-2 0.06 0.12
Ciprofloxacin ≤0.008-2 0.015 0.06
Ampicillin 32->128 64 >128
Cefuroxime 1->128 4 64
Ceftriaxone 0.03->128 0.12 32
Imipenem 0.12-1 0.25 0.5
Amoxicillin-clavulanic acid 1->128 8 32
Gentamicin 0.25->128 0.5 2
Proteus vulgaris (42)
Gemifloxacin 0.015-16 0.25 1
Moxifloxacin 0.12-16 0.5 4
Gatifloxacin 0.015-2 0.12 0.5
Levofloxacin 0.015-1 0.06 0.25
Ciprofloxacin 0.015-1 0.03 0.25
Ampicillin 2->128 >128 >128
Cefuroxime 1->128 >128 >128
Ceftriaxone ≤0.008-4 0.12 1
Imipenem 0.03-8 2 4
Amoxicillin-clavulanic acid 0.12->128 8 64
Gentamicin 0.25-16 0.5 4
P. mirabilis (63)
Gemifloxacin 0.03-16 0.25 8
Moxifloxacin 0.06-64 1 8
Gatifloxacin 0.03-16 0.25 2
Levofloxacin 0.03-8 0.12 2
Ciprofloxacin 0.015-4 0.06 1
Ampicillin 1->128 128 >128




Cefuroxime 0.5->128 4 32
Ceftriaxone ≤0.008-64 0.015 2
Imipenem 0.06-8 1 4
Amoxicillin-clavulanic acid 0.5->128 4 64
Gentamicin 0.25->128 2 >128
Non-typhoidal Salmonella spp. (36)
Gemifloxacin ≤0.008-0.5 0.03 0.12
Moxifloxacin ≤0.008-4 0.12 1
Gatifloxacin ≤0.008-0.5 0.06 0.25
Levofloxacin 0.015-0.5 0.06 0.5
Ciprofloxacin ≤0.008-0.5 0.015 0.25
Ampicillin 0.5->128 2 >128
Cefuroxime 2-16 8 8
Ceftriaxone 0.03-1 0.12 0.12
Imipenem 0.12-2 0.12 0.5
Amoxicillin-clavulanic acid 0.5->128 2 4
Gentamicin 0.5-16 0.5 2
Citrobacter freundii (62)
Gemifloxacin ≤0.008-64 0.5 16
Moxifloxacin 0.015-128 1 16
Gatifloxacin 0.015-32 0.5 4
Levofloxacin 0.015-32 0.25 8
Ciprofloxacin ≤0.008-32 0.06 4
Ampicillin 2->128 >128 >128
Cefuroxime 2->128 64 >128
Ceftriaxone 0.015->128 0.5 >128
Imipenem 0.03-4 0.25 0.5
Amoxicillin-clavulanic acid 8->128 128 >128
Gentamicin 0.12->128 1 >128
Enterobacter cloacae (61)
Gemifloxacin ≤0.008-64 0.25 16
Moxifloxacin 0.015-128 2 16
Gatifloxacin 0.015-32 0.25 16
Levofloxacin ≤0.008-32 0.12 16
Ciprofloxacin ≤0.008->128 0.12 16
Ampicillin 2->128 >128 >128
Cefuroxime 2->128 >128 >128
Ceftriaxone 0.03->128 16 >128
Imipenem 0.06-4 0.5 2
Amoxicillin-clavulanic acid 2->128 64 >128
Gentamicin 0.25->128 2 >128
Morganella morganii (44)
Gemifloxacin 0.03-32 0.25 16
Moxifloxacin 0.03-64 1 32
Gatifloxacin 0.03-32 0.25 8
Levofloxacin 0.03-32 0.12 8
Ciprofloxacin ≤0.008-128 0.06 8
Ampicillin 16->128 >128 >128
Cefuroxime 8->128 128 >128
Ceftriaxone ≤0.008->128 0.5 32
Imipenem 1-4 2 4
Amoxicillin-clavulanic acid 64->128 >128 >128
Gentamicin 0.25->128 1 64
Providencia spp. (32)
Gemifloxacin 0.06->128 2 16
(Continued next page)
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(15). Although all of the isolates were inhibited by ≤1 mg/L
of all of the fluoroquinolones tested, gemifloxacin had the
lowest MIC50, and MIC90, regardless of -lactamase production.
This finding is consistent with other reports (5-7, 16, 17).
The MIC90s of gemifloxacin for methicillin-susceptible S.
aureus (MSSA), and methicillin-susceptible, and -resistant coag-
ulase-negative staphylococci were 0.12, 0.12, and 1 mg/L,
respectively (Table 2). In the present study, gemifloxacin was
2 to 128-fold more potent than the other quinolones (MIC90
0.25-128 mg/L), and 2 to ≥128-fold more potent than the
non-quinolone comparators (MIC90 0.25->128 mg/L) for these
isolates. Most of the methicillin-resistant S. aureus (MRSA)
isolates were less susceptible than MSSA to all of the fluoro-
quinolones.
None of the E. faecalis isolates in this study were resistant to
vancomycin, while 20% of the Enterococcus faecium isolates were
vancomycin resistant (Table 2). The MIC50 (0.25 mg/L), and
MIC90 (8 mg/L) of gemifloxacin were 2 to 8-fold lower than
the other quinolones for E. faecalis. Gemifloxacin was the most
potent of the fluoroquinolones studied against E. faecalis;
however, strains with reduced gemifloxacin susceptibilities
were noted, particularly in E. faecium. For streptococci other
than S. pneumoniae, the MIC90 of gemifloxacin was 0.25 mg/L,
which was 1- to 16-fold lower than that of the other quinolones.
The in vitro activity of fluoroquinolones against Gram-
negative bacilli was found to vary significantly, depending
on species. In general, the MICs of ciprofloxacin were lower
than those of the other quinolones for Gram-negative bacilli,
except for E. coli, Providencia spp., Acinetobacter baumannii, and
Stenotrophomonas maltophilia. The MIC90s of gemifloxacin for
K. oxytoca, Proteus vulgaris, and non-typhoidal Salmonella
were 0.25, 1.0, and 0.12 mg/L, respectively, while those for
other Enterobacteriaceae were 4-64 mg/L, which were similar
to or slightly higher than those of ciprofloxacin (Table 3). None
of the N. gonorrhoeae isolates tested were susceptible to peni-
cillin. The MIC90 of ciprofloxacin was 0.5 mg/L, and 92% of
N. gonorrhoeae were non-susceptible to ciprofloxacin. This rate
was higher than that of other reports. Ciprofloxacin-non-sus-
Moxifloxacin 0.12->128 1 32
Gatifloxacin 0.12->128 2 32
Levofloxacin 0.06->128 1 32
Ciprofloxacin 0.03->128 0.5 64
Ampicillin 0.25->128 64 >128
Cefuroxime ≤0.06->128 2 64
Ceftriaxone ≤0.008->128 0.03 0.5
Imipenem 0.5-8 1 4
Gentamicin 0.25->128 8 128
Amoxicillin-clavulanic acid 0.25->128 64 >128
Serratia marcescens (61)
Gemifloxacin 0.03->128 2 16
Moxifloxacin 0.25-64 8 16
Gatifloxacin 0.06-64 2 8
Levofloxacin 0.03-64 2 8
Ciprofloxacin ≤0.008-64 1 8
Ampicillin 8->128 >128 >128
Cefuroxime 32->128 >128 >128
Ceftriaxone 0.12->128 32 >128
Imipenem 0.5-64 2 8
Amoxicillin-clavulanic acid 8->128 >128 >128
Gentamicin 0.25->128 16 >128
Pseudomonas aeruginosa (83)
Gemifloxacin 0.25->128 4 128
Moxifloxacin 0.5->128 16 128
Gatifloxacin 0.5-128 4 64
Levofloxacin 0.25-128 4 64
Ciprofloxacin ≤0.06-64 1 32
Ceftazidime 1-128 16 64
Imipenem 0.25-128 2 16
Gentamicin 0.5->128 8 >128
Acinetobacter baumannii (84)
Gemifloxacin 0.015-64 8 64




Moxifloxacin 0.015-64 8 32
Gatifloxacin 0.03-32 4 16
Levofloxacin 0.06-32 4 16
Ciprofloxacin 0.06->128 32 128
Ampicillin 8->128 >128 >128
Cefuroxime 8->128 >128 >128
Ceftriaxone 4->128 >128 >128
Imipenem 0.06-32 1 8
Gentamicin 0.25->128 128 >128
Amoxicillin-clavulanic acid 0.5->128 16 128
Stenotrophomonas maltophilia (63)
Gemifloxacin 0.12-16 1 4
Moxifloxacin 0.12-16 1 4
Gatifloxacin 0.06-8 0.5 4
Levofloxacin 0.015-16 0.5 4
Ciprofloxacin 0.5-32 2 16
Ampicillin 64->128 >128 >128
Cefuroxime 1->128 >128 >128
Ceftriaxone 32->128 >128 >128
Imipenem 32->128 >128 >128
Gentamicin 1->128 128 >128
Amoxicillin-clavulanic acid 16->128 64 >128
Neisseria gonorrhoeae (49)
Gemifloxacin ≤0.008-8 0.12 0.5
Moxifloxacin ≤0.008-4 0.25 0.5
Gatifloxacin ≤0.008-4 0.12 0.25
Levofloxacin ≤0.008-8 0.5 0.5
Ciprofloxacin ≤0.008-32 0.5 0.5
Penicillin 0.25->128 32 >128
Ceftriaxone ≤0.008-0.12 0.03 0.06
Tetracycline 0.5-4 2 4
Spectinomycin 2-32 16 32
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ceptible N. gonorrhoeae also showed reduced susceptibility to
other fluoroquinolones, but the MIC50s of gemifloxacin, and
gatifloxacin were 4-fold lower than that of ciprofloxacin.
The quinolones are absorbed quickly, attaining maximum
plasma concentration within 1-2 hr of oral administration.
The maximum plasma concentrations (bronchial mucosa:
plasma ratios) were 1.2 mg/L (7.2), 1.2 mg/L (2.1), 3.9 mg/L
(1.7), 5.1 mg/L (1.6), and 2.3 mg/L (1.7) with a single oral
administration of 320 mg gemifloxacin, 200 mg moxifloxacin,
400 mg gatifloxacin, 500 mg levofloxacin, and 500 mg
ciprofloxacin, respectively (18, unpublished data). Therefore,
it was considered those concentrations of fluoroquinolones in
bronchial mucosa were 8.6, 2.5, 6.6, 8.2, 3.9 mg/L, respectively.
In conclusion, gemifloxacin was most active in vitro against
Gram-positive species, including respiratory pathogens isolated
in Korea. Therefore, gemifloxacin should be useful for the
treatment of the majority of respiratory, and other infections,
especially those due to Gram-positive cocci.
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